Clinical Trial Update: DC Vaccine for Patients With Ductal Carcinoma In Situ [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update for a dendritic cell vaccine targeting ductal carcinoma in situ (DCIS) within breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Ductal Carcinoma in Situ

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Breast Cancer, DCIS | Phase 1, Phase 2 | Status: COMPLETED